Press Releases

May 22, 2018

FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes
May 21, 2018

New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma

* In steroid-sparing VENTURE trial, Dupixent-treated patients substantially reduced use of oral corticosteroids, yet had fewer exacerbations and improved lung function compared to placebo.
May 16, 2018

Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

* U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018
May 1, 2018

Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients

-- Agreement provides Praluent at lower net price and enables streamlined patient access based on physician attestation
Apr 30, 2018

FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

Show per page

Print
Email page
RSS